WO2008108927A2 - Procédés et compositions de stabilisation de polypeptides - Google Patents

Procédés et compositions de stabilisation de polypeptides Download PDF

Info

Publication number
WO2008108927A2
WO2008108927A2 PCT/US2008/002261 US2008002261W WO2008108927A2 WO 2008108927 A2 WO2008108927 A2 WO 2008108927A2 US 2008002261 W US2008002261 W US 2008002261W WO 2008108927 A2 WO2008108927 A2 WO 2008108927A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
composition
solution
polypeptide
sodium
Prior art date
Application number
PCT/US2008/002261
Other languages
English (en)
Other versions
WO2008108927A3 (fr
Inventor
Gabriel Sosne
David Crockford
Original Assignee
Regenerx Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals, Inc. filed Critical Regenerx Biopharmaceuticals, Inc.
Publication of WO2008108927A2 publication Critical patent/WO2008108927A2/fr
Publication of WO2008108927A3 publication Critical patent/WO2008108927A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present invention is in the field of stabilizing polypeptides.
  • Polypeptides in aqueous solutions tend to be unstable and degrade over time.
  • a method of stabilizing a polypeptide outside of a body comprises combining a polypeptide with an aqueous solution or gel containing substantially physiological levels of electrolytes and salts.
  • the invention further relates to aqueous solutions or gel containing polypeptides and substantially physiological levels of electrolytes and salts.
  • a method of stabilizing a polypeptide outside of a body comprises combining a polypeptide with an aqueous solution or gel containing substantially physiological levels of electrolytes and salts.
  • the polypeptide is solubilized in the solution or gel.
  • the polypeptide may comprise at least one of T ⁇ 4, an isoform of T ⁇ 4, an N-terminal fragment of T ⁇ 4, a C- terminal fragment of T ⁇ 4, an N-terrriinal variant of T ⁇ 4, a C-terminal variant of T ⁇ 4, T ⁇ 4ala, T ⁇ 9, T ⁇ 10, T ⁇ 11 , T ⁇ 12, T ⁇ 13, T ⁇ 14, T ⁇ 15, gelsolin, vitamin D binding protein (DBP) profilin, cofilin, adsevertin, propomyosin, fincilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, ⁇ -actinin or acumentin, T ⁇ 4 sulfoxide, an LKKTET peptide or a conservative variant thereof, an LKKTNT peptide or a conservative variant thereof, a KLKKTET peptide or a conservative variant thereof, an LKKTETQ peptide or a conservative variant thereof, an actin-sequester
  • the polypeptide comprises T ⁇ 4 or an isoform of T ⁇ 4, such as T ⁇ 4ala, T ⁇ 9, T ⁇ 10, T ⁇ 11 , T ⁇ 12, T ⁇ 13, T ⁇ 14, or T ⁇ 15.
  • the polypeptide comprises T ⁇ 4.
  • the solution is formed with at least one tonicity adjusting agent, at least one buffering agent, at least one of an acidic or basic pH-adjusting agent capable of adjusting pH of the composition to a desired pH level, or combinations thereof.
  • the solution preferably has a pH within a range of about 5.0-7.5, more preferably within a range of about 5.5-7.0, and still more preferably within a range of about 5.5-6.5.
  • the solution is formed with a plurality of electrolyte and salt components selected from sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, sodium citrate dihydrate and sodium hydroxide. It is particularly preferred that the solution is formed with at least one of calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, and sodium citrate dihydrate. Still more preferably, the solution comprises a plurality of components selected from the group consisting of calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate and sodium citrate dihydrate.
  • the solution is formed with all of said electrolyte and salt components so as to form said solution with said components at concentrations within about 3-10 mg/ml sodium chloride, about 0.05-1.5 mg/ml potassium chloride, about 0.1-1 mg/ml calcium chloride dihydrate, about 0.05-1 mg/ml magnesium chloride hexahydrate, about 2-6 mg/ml sodium acetate trihydrate, about 1-3 mg/ml sodium citrate dihydrate and sodium hydroxide in an amount effective to provide the solution with a pH within a range of about 5-7.8.
  • compositions formed as described above, and containing components as described above are applicable to compositions formed as described above, and containing components as described above.
  • One particularly preferred composition comprises an aqueous solution of a polypeptide comprising T ⁇ 4 solubilized in a solution comprising about 6.4 mg/ml sodium chloride, about 0.75 mg/ml potassium chloride, about 0.48 mg/ml calcium chloride dihydrate, about 0.3 mg/ml magnesium chloride hexahydrate, about 3.9 mg/ml sodium acetate trihydrate, about 1.7 mg/ml sodium citrate dihydrate and sodium hydroxide in an amount effective to provide the solution with a pH within a range of about 6.9-7.1.
  • the aqueous portion of the solution preferably is sterile water for injection (USP).
  • the polypeptide may be present in the solution at a concentration within a range of about 0.001-1 ,000 mg/ml, preferably within a range of about 0.01-700 mg/ml, more preferably within a range of about 0.01-10 mg/ml, still more preferably within a range of about 0.05-5 mg/ml, and even more preferably within a range of about 0.1-1.5 mg/ml.
  • the composition is an aqueous gel comprising about 1-5% (preferably about 2.5%) carboxymethyl cellulose, about 0.01-0.1 % (preferably about 0.02%) propylparaben, about 0.01-0.2% (preferably about 0.1 %) methylparaben, about 0.2-2% (preferably about 1%) propylene glycol, about 5-15 (preferably about 10) mM sodium phosphate, about 100-140 (preferably about 120) mM sodium chloride and purified water, at a pH within a range of about 5.5-6.5 (preferably about 5.7).
  • compositions may include, without limitation, ophthalmic, injectable, infusible, parenteral and topical formulations, and the like.
  • an inventive solution, composition or formulation containing the polypeptide is stored in a substantially stearate-free container, more preferably in a substantially polyethylene-free container, and still more preferably in a container comprising polypropylene which is substantially polyethylene-free.
  • Thymosin beta 4 was initially identified as a protein that is up-regulated during endothelial cell migration and differentiation in vitro. Thymosin beta 4 was originally isolated from the thymus and is a 43 amino acid, 4.9 kDa ubiquitous polypeptide identified in a variety of tissues. Several roles have been ascribed to this protein including a role in a endothelial cell differentiation and migration, T cell differentiation, actin sequestration, vascularization, wound-healing and organ repair.
  • the invention is preferably applicable to Thymosin ⁇ 4, and/or T ⁇ 4 isoforms, analogues or derivatives, including KLKKTET, LKKTETQ, oxidized T ⁇ 4, T ⁇ 4 sulfoxide, N-terminal variants of T ⁇ 4 and C-terminal variants of T ⁇ 4.
  • compositions which may be used in accordance with the present invention include polypeptides or peptide agents such as Thymosin ⁇ 4 (T ⁇ 4), and/or T ⁇ 4 isoforms, analogues or derivatives, including oxidized forms of T ⁇ 4 including T ⁇ 4 sulfoxide, N-terminal variants of T ⁇ 4, and C-terminal variants of T ⁇ 4, and polypeptides or peptide fragments comprising or consisting essentially of the amino acid sequence LKKTET and conservative variants thereof.
  • T ⁇ 4 Thymosin ⁇ 4
  • T ⁇ 4 Thymosin ⁇ 4
  • PCT/US99/17282 discloses isoforms of T ⁇ 4 which may be useful in accordance with the present invention as well as amino acid sequence LKKTET or LKKTNT and conservative variants thereof, which may be utilized with the present invention.
  • International Application Serial No. PCT/GB99/00833 discloses oxidized Thymosin ⁇ 4 which may be utilized in accordance with the present invention.
  • T ⁇ 4 and T ⁇ 4 isoforms are described primarily hereinafter with respect to T ⁇ 4 and T ⁇ 4 isoforms, it is to be understood that the following description is intended to be equally applicable to the other polypeptides described herein, including but not limited to amino acid sequence LKKTET or LKKTNT, peptides and fragments comprising or consisting essentially of LKKTET or LKKTNT, conservative variants thereof and/or T ⁇ 4 isoforms, analogues or derivatives, including oxidized T ⁇ 4, N-terminal variants of T ⁇ 4, and C-terminal variants of T ⁇ 4.
  • T ⁇ 4 isoforms have been identified and have about 70%, or about 75%, or about 80% or more homology to the known amino acid sequence of T ⁇ 4.
  • Such isoforms include, for example, T ⁇ 4ala, T ⁇ 9, T ⁇ 10, T ⁇ 11 , T ⁇ 12, T ⁇ 13, T ⁇ 14 and T ⁇ 15. Similar to T ⁇ 4, the T ⁇ 10 and T ⁇ 15 isoforms have been shown to sequester actin.
  • T ⁇ 4, T ⁇ 10 and T ⁇ 15, as well as these other isoforms share an amino acid sequence, LKKTET or LKKTNT, that appears to be involved in mediating actin sequestration or binding.
  • T ⁇ 4 has anti-inflammatory activity, and also can modulate actin polymerization (e.g.
  • T ⁇ 4's ability to modulate actin polymerization may be due to its ability to bind to or sequester actin via the LKKTET or LKKTNT sequence.
  • T ⁇ 4 isoforms such as T ⁇ 4ala, T ⁇ 9, T ⁇ 10, T ⁇ 11 , T ⁇ 12, T ⁇ 13, T ⁇ 14 and T ⁇ 15, as well as T ⁇ 4 isoforms not yet identified, will be particularly applicable in the methods and compositions of the invention.
  • polypeptides, agents or proteins having anti inflammatory activity and/or actin sequestering or binding capability, or that can mobilize actin or modulate actin polymerization, as demonstrated in an appropriate sequestering, binding, mobilization or polymerization assay, or identified by the presence of an amino acid sequence that mediates actin binding, such as LKKTET or LKKTNT, for example, can similarly be employed in preferred methods and compositions of the invention.
  • Such proteins may include gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, Dnasel, vilin, fragmin, severin, capping protein,, ⁇ -actinin and acumentin, for example.
  • the invention further provides compositions comprising gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, ⁇ -actinin and acumentin as set forth herein.
  • DBP vitamin D binding protein
  • conservative variant denotes the replacement of an amino acid residue by another, biologically similar residue.
  • conservative variations include the replacement of a hydrophobic residue such as isoleucine, valine, leucine or methionine for another, the replacement of a polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like.
  • a composition of the invention contains a peptide agent as described herein at a concentration within a range of from about 0.001 micrograms per ml (mcg/ml) to about 1 ,000 mg/ml, about 0.1-100 mcg/ml, or about 1-10 mcg/ml.
  • compositions using or containing a polypeptide, peptide agent or composition as described herein may be further formulated into formulations by admixture with other ophthalmically, pharmaceutically or cosmetically acceptable non-toxic excipients or carriers.
  • compositions and formulations may be in a form of a solution, lotion, salve, gel, cream, paste, spray, suspension, dispersion, hydrogel, foam or ointment, or the like, without limitation.
  • a topical formulation containing the active compound can also contain other physiologically compatible vehicles, as those skilled in the art can select using conventional criteria.
  • the other vehicles can be selected from the known ophthalmic, pharmaceutical or cosmetic vehicles which may include, but are not limited to water polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, petroleum derivatives such as mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as carboxypolymethylene gel, vegetable fats such as peanut oil and polysaccharides such as dextrans, and glycosaminoglycans such as sodium hyaluronate and salts such as sodium chloride and potassium chloride.
  • water polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, petroleum derivatives such as mineral oil and white
  • excipients and additives such as stabilizers, solubilizers, tonicity enhancing agents, buffer substances, preservatives, thickeners, complexing agents and other excipients may be used.
  • additives and excipients can be found in U.S. Pat. Nos. 5,134,124 and 4,906,613.
  • preservatives and/or other excipients are added to an ophthalmic composition.
  • the formulation may be suitable for topical or general administration, such as for example aqueous solutions, mixtures of water and water-miscible solvents, such as Ci - C 7 -alkanols, vegetable oils or mineral oils comprising from 0.5 to 5% by weight hydroxyethylcellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone and other non-toxic water-soluble polymers, such as, for example, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose and hydroxypropylcellulose, acrylates or methacrylates, such as salts of polyacrylic acid or ethyl acrylate, polyacrylamides, natural products, such as gelatin, alginates, pectins, tragacanth, karaya gum, xanthan gum, carrageenin, agar and acacia, starch
  • Preferred additives include cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose and hydroxypropylcellulose, neutral Carbopol, or mixtures thereof.
  • solubilizers used for a formulation of the present invention include, for example, tyloxapol, fatty acid glycerol poly-lower alkylene glycol esters, fatty acid poly-lower alkylene glycol esters, polyethylene glycols, glycerol ethers or mixtures of those compounds.
  • the amount added is typically sufficient to solubilize the active ingredient.
  • the concentration of the solubilizer is from 0.1 to 5000 times the concentration of the active ingredient.
  • Lower alkylene means linear or branched alkylene with up to and including 7 C-atoms.
  • Examples are methylene, ethylene, 1 ,3- propylene, 1 ,2-propylene, 1 ,5-pentylene, 2,5-hexylene or 1 ,7-heptylene.
  • Lower alkylene is preferably linear or branched alkylene with up to and including 4 C-atoms.
  • buffer substances are acetate, ascorbate, borate, hydrogen carbonate/carbonate, citrate, gluconate, lactate, phosphate, propionate and TRIS (tromethamine) buffers.
  • Tromethamine and borate buffer are preferred buffers.
  • the amount of buffer substance added is, for example, that necessary to ensure and maintain a physiologically tolerable pH range.
  • Tonicity enhancing agents are, for example, ionic compounds, such as alkali metal or alkaline earth metal halides, such as, for example, CaCI 2 , KBr, KCI, LiCI, NaBr, NaCI, or boric acid.
  • Non-ionic tonicity enhancing agents are, for example, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose.
  • sufficient tonicity enhancing agent is added to impart to the ready-for-use ophthalmic composition an osmolality of approximately from 50 to 1000 mOsmol, preferred from 100 to 400 mOsmol, more preferred from 200 to 400 mOsmol and even more preferred from 280 to 350 mOsmol.
  • preservatives are quaternary ammonium salts, such as cetrimide, benzalkonium chloride or benzoxonium chloride, alkyl-mercury salts of thiosalicylic acid, such as, for example, thimerosal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate, parabens, such as, for example, methylparaben and/or propylparaben, alcohols, such as, for example, chlorobutanol, benzyl alcohol or phenyl ethanol, guanidine derivatives, such as, for example, chlorohexidine or polyhexamethylene biguanide, or sorbic acid.
  • quaternary ammonium salts such as cetrimide, benzalkonium chloride or benzoxonium chloride
  • alkyl-mercury salts of thiosalicylic acid such as, for example, thimerosal
  • Preferred preservatives are cetrimide, benzalkonium chloride, benzoxonium chloride and parabens. Where appropriate, a sufficient amount of preservative may be added to the composition to ensure protection against secondary contaminations during use caused by bacteria and fungi.
  • compositions may comprise further non-toxic excipients, such as, for example, emulsifiers, wetting agents or fillers, such as, for example, the polyethylene glycols designated 200, 300, 400 and 600, or Carbowax designated 1000, 1500, 4000, 6000 and 10 000.
  • excipients such as, for example, emulsifiers, wetting agents or fillers, such as, for example, the polyethylene glycols designated 200, 300, 400 and 600, or Carbowax designated 1000, 1500, 4000, 6000 and 10 000.
  • excipients that may be used if desired are listed below but they are not intended to limit in any way the scope of the possible excipients.
  • complexing agents such as disodium-EDTA or EDTA
  • antioxidants such as ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butyl-hydroxyanisole, butyl-hydroxy-toluene or ⁇ -tocopherol acetate
  • stabilizers such as a cyclodextrin, thiourea, thiosorbitol, sodium dioctyl sulfosuccinate or monothioglycerol
  • excipients such as, for example, lauric acid sorbitol ester, triethanol amine oleate or palmitic acid ester.
  • Preferred exipients are complexing agents, such as disodium-EDTA and stabilizers, such as a cyclodextrin.
  • the amount and type of excipient added is in accordance with the particular requirements and is generally in the range of from approximately 0.0001 to approximately 90% by weight.
  • a cyclodextrin is composed of several glucose units which have three free hydroxy groups per glucose.
  • the amount of a cyclodextrin used in accordance with one embodiment may preferably range from 0.01-20% by weight, more preferably from 0.1-15% by weight and even more preferably from 1-10% by weight.
  • a formulation may include another therapeutically effective pharmaceutical agent which may be, for example, an antibiotic, an antiallergic, an anesthetic, another antiphlogistic, a corticosteroide, an agent suitable for lowering intraocular pressure, or another drug.
  • another therapeutically effective pharmaceutical agent which may be, for example, an antibiotic, an antiallergic, an anesthetic, another antiphlogistic, a corticosteroide, an agent suitable for lowering intraocular pressure, or another drug.
  • pH hydrogen ion concentration
  • the pH of ophthalmic formulations should be as close to that of the tear film as possible.
  • the physiologic pH of tears is approximately 7.4 ⁇ 0.2. Thus, from a comfort, tolerability and safety perspective, this would be the optimal pH of ophthalmic preparations.
  • Tear fluid is capable of quickly diluting and buffering small volumes of added substances, suggesting the eye can tolerate a fairly wide pH range offered by certain formulations.
  • ophthalmic formulations may be within a range of from about pH 3.5 -11.5. However, ophthalmic formulations may display pH ranges somewhat more narrowly from 5.0-7.5.
  • buffer systems are composed of a weak acid or base and its conjugate salt.
  • the buffering capacity of the components in the system acts in such a way that, despite the addition of an acid or base and exposure to external influences of temperature, pressure, volume, redox potential, body fluids and tears, the pH will remain essentially constant.
  • buffer capacity should be large enough to resist changes in the product pH (i.e., pH drift) for a reasonable shelf-life (i.e., under storage conditions)
  • the buffer capacity of inventive ophthalmic formulations should be low enough to allow rapid readjustment of the product to physiologic pH upon administration to the eye.
  • buffer capacities for ophthalmic products should be within the range of 0.05 to 1.0.
  • Preferred and most preferred buffer capacities range from 0.02 to 0.2 and 0.01 to 0.1 , respectively for certain inventive compositions.
  • Buffer capacity is determined by the following formula:
  • appropriate buffer systems may be sodium salts of the following acids: acetic; ascorbic; boric; carbonic; phosphoric; citric; gluconic; lactic; and propionic.
  • Calcium salts of carbonic or propionic acid form appropriate buffer systems as do potassium salts of phosphoric acid.
  • Tris buffer tromethamine
  • Other preferred buffers are acetate, phosphate, citrate and borate.
  • a buffer system involving proton donor and proton acceptor groups of the amino acid residues of proteins may be preferable to the acid-base or an amine-base buffer.
  • the specific amount of a buffer substance used will vary and depends upon the amount that is deemed necessary to maintain a pH-environment suitable for the stability of inventive composition and to ensure and maintain a physiologically tolerable pH range.
  • the objective is to adjust the tonicity of the inventive ophthalmic compositions to that of natural tears to approximate physiological tonicity (e.g., 0.9% saline).
  • physiological tonicity e.g. 0.9% saline
  • sodium chloride, potassium chlorides, calcium chloride, dextrose and/or mannitol may be added to the inventive peptide agent formulation.
  • the amount of tonicity agent will vary, depending on the particular agent to be added.
  • certain inventive compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality preferably 150-450 mOsm and most preferably 250-350 mOsm.
  • the preferred tonicity agents are sodium salts and potassium salts, particularly sodium and potassium chloride.
  • the most preferred tonicity agent is sodium chloride.
  • compounds may be included which sooth the eye, reduce surface tension and improve wettability (contact) of an otherwise hydrophobic epithelial corneal surface, approximate the consistency of tears. Such compounds may also enhance the viscosity of the inventive compositions, allowing an inventive formulation to remain in the eye longer thus giving the peptide agent more time to exert its therapeutic activity or undergo absorption to reach the desired target.
  • Suitable viscosity enhancers in ophthalmic formulations and their concentration ranges used in certain inventive compositions include but are not limited to: (a) Monomeric polyols, such as tyloxapol (0.1-2%), glycerol (0.2-2%), propylene glycol (0.2 -2%), ethylene glycol (0.2-2%); (b) Polymeric polyols, such as polyethylene glycol (e.g., PEG 300, PEG 400)(0.2-1 %); (c) Cellulose derivatives (polymers of the cellulose family), such as hydroxyethylcellulose (0.2-2.5%), hypromellose (0.2 to 2.5%), hydroxypropylmethyl cellulose (0.2-2.5%), methycellulose (0.2-2.5%), carboxymethylcellulose sodium (0.2 to 2.5%), hydroxylpropylcellulose (0.2-2.5%); (d) Dextrans, such as dextran 70 (0.1% when used with another polymeric demulcent agent); (e) Water-soluble proteins such as
  • More than one viscosity enhancer may be added to an inventive composition to increase the viscosity of the carrier (vehicle).
  • a preferred enhancer in the carrier of an inventive peptide agent formulation is carboxymethycellulose.
  • Viscosity describes a material's internal resistance to flow or change in form, when a stress is applied.
  • the viscosity of a material (solution, semi-viscous gel, suspension, oleaginous ointments and ointment gels (viscous gels) is given in poise units.
  • the unit, centipoise (“cp" or the plural "cps") is equal to 0.01 poise and is most often used in pharmaceutical applications.
  • Compounds used to enhance viscosity are available in various grades such as 15 cps, 100 cps, etc., etc.
  • the grade number refers to the viscosity which results when a fixed percentage aqueous solution of the enhancer is made. Generally, solutions are 1% or 2%; however, they can be as high as 4% with certain enhancers. Viscosity is measured at 20° or 25° C.
  • a suitable viscosity in an ophthalmic solution is between 25 and 50 centipoises (cps).
  • concentration of an enhancer required to produce that desired viscosity will depend on the grade of the enhancer. For example, if methycellulose 25 cps is used, a 1 % solution will create a viscosity of 25 cps. If methycellulose 4000 cps is used, a 0.25% solution provides the desired viscosity. Standard references give tables of viscosities produced by percentage solutions and grades of ingredients.
  • inventive formulations will exhibit a viscosity of >1 to 100,000 centipoises (cps) or greater.
  • Inventive ointment compositions may have viscosity grades that are greater than 100,000 cps. This is because ophthalmic ointments are intended to be thick when standing to prevent them from flowing away from the intended area of use. Following application and over time, temperatures within the conjunctival sac, or on the surface of the eye, where these ointments are deposited, will cause these ointments to "melt" and begin to flow.
  • inventive compositions have the potential to be degraded by oxidation. Consequently, steps during the manufacture, control and packaging of an inventive composition may include protecting inventive compositions, susceptible to oxidation, by (1 ) displacing oxygen with nitrogen or a dense inert gas such as argon, (2) adding a reducing agent to minimize oxidative effects, (3) the introduction of a decoy molecule.
  • Common antioxidant (reducing) agents which may be used in ophthalmic formulations up to a concentration of 0.1% or more are sodium sulfite, sodium thiosulfite, sodium bisulfite, sodium metabisulfite, and thiourea. Sulfites can cause allergic-type reactions in certain people; consequently, patients receiving this type of antioxidant should be questioned about this potential reaction before being treated with an inventive composition containing the antioxidant.
  • Other useful antioxidants compatible with the inventive compositions are ascorbic acid, EDTA/disodium edetate, acetic acid, citric acid, glutathione and acetylcysteine. These agents may also be regarded as stabilizers.
  • a decoy molecule or an oxygen sequestering protective agent may be added as stabilizers to an inventive formulation to minimize oxidative effects on the inventive formulation.
  • the molecular decoy must have at least the same capability of being oxidized as the inventive formulation.
  • One such decoy, for an inventive composition containing methionine is the amino acid, methionine, itself. Free methionine added to an inventive composition containing the amino acid methionine would compete for oxygen in the process of being oxidized to methionyl sulfoxide.
  • a free oxygen-consuming agent is one that prevents other oxygen-reactive amino acids in the inventive composition/preptide from being oxidized. For the purposes of certain inventive compositions but not limited to such, a free oxygen-consuming agent is methionine.
  • Ophthalmic ointments tend to keep an active agent in contact with the eye longer than suspensions and certainly solutions. Most ointments, tend to blur vision, as they are not removed easily by the tear fluid. Thus, ointments are generally used at night as adjunctive therapy to eye drops used during the day.
  • Oleaginous ointment bases of inventive compositions are mixtures of mineral oil, petrolatum and lanolin all have a melting point close to body temperature.
  • the compositions may include mineral oil, petrolatum or lanolin.
  • preferred compositions would include a combination of petrolatum, mineral oil and lanolin.
  • the most preferred composition is an ointment combination containing white petrolatum, mineral oil and lanolin (anhydrous).
  • the peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant thereof is dissolved in a small amount of purified water or 0.9% saline to affect dissolution.
  • This aqueous solution is incorporated into anhydrous lanolin and the then "liquid" lanolin (up to 10%) is mixed with the remaining ointment/oleaginous emollient base ingredients, mineral oil (up to 30%) and white petrolatum (up to 60%).
  • Ophthalmic ointment tubes are typically small holding approximately 1-5 grams of ointment, preferably 3.5 grams, and fitted with narrow gauge tips which permit the extrusion of narrow bands of ointment measured in inches or fractions thereof for dosing purposes.
  • Sterility is an absolute requirement of all ophthalmic formulations. Contaminated formulations may result in eye infections that could ultimately cause blindness, especially if the P. aeruginosa microbe is involved. Therefore, ophthalmic formulations as described herein must be prepared using techniques, unique for solutions, gels, suspensions and ointments of the inventive compositions that assure sterility. Sterile formulations must be packaged in sterile containers. Many topical ophthalmic products are typically packaged in multidose form. In such multidose forms, preservatives are required to prevent microbial contamination of an otherwise sterile product during use.
  • Suitable preservatives include: Quaternary ammonium compounds (salts), such as benzalkonium chloride (0.001 to 0.02%), benzethonium chloride, cetalkonium chloride, cetrimide, benzododecinium bromide and benzoxonium chloride; Alkyl-mercury salts of thiosalicylic acid, such as thimerosal (0.001 to 0.005%); Parabens, such as methylparaben and propylparaben; Chelating agents, such as disodium edetate, sodium gluconate, sodium propionate; Other agents, such as chlorobutanol, boric acid, sorbic acid, phenylethanol (0.25%); Purite® chlorine dioxide; Polyquad® polyquatemium-1 (0.001%); and Aldox® myristamidopropyl diethylamine(0.005%); or other agents known to those skilled in the art.
  • Quaternary ammonium compounds such as benzal
  • Such preservatives are typically employed at a level of from 0.001 % to 1.0% (w/v) to ensure protection against secondary microbial contaminations during use caused by bacteria, mold, and fungi.
  • preservatives for use in the inventive formulations are the combination of methylparaben (0.080% -.1%) and propylparaben (0.016% - 0.024%), benzalkonium chloride (BAK) (0.005% - 0.02%, where 0.01% w/v is most preferred), a combination of BAK and EDTA (0.01-0.5%), which when used together have synergistic effects.
  • compositions of the present invention will be sterile but unpreserved. Such compositions for the most part will not contain preservatives. Consequently, these compositions cannot be re-used and once-opened they must be discarded.
  • Bulking/stabilizing agent(s) may be advantageous to maintain the hydration state of a lubricant, emollient or vehicle enhancer comprising an inventive composition during long-term storage. Associations appear to occur within or among polymer chains of these substances which after time favor the reduction of hydration state of these chains. These associations may be in the form of hydrogen bonds within and among the polymer chains which can manifest as a change in viscosity and texture of an ophthalmic formulation/composition in the present invention. Lyophilization bulking agents, which are principally sugars, may also be considered stress protectants, protecting compounds during the lyophilization cycle.
  • Agents which greatly decelerate or eliminate this reduced state of hydration are a class of stabilizing or hydration-enhancing agents, the polyols at concentrations of 0.2 to 5% by weight.
  • Representatives of such polyols are mannitol, sorbitol, glycerol, sucrose, related sugars, and the like.
  • a most preferred stabilizing agent is the hydroscopic mannitol at concentrations ranging from 0.2% to 5% by weight.
  • 5OmM amino acid stabilizers such as alanine (Ala), lysine (Lys), glycine (GIy) and glutamic acid (GIu) have been incorporated into the formulated peptide agent containing sequence LKKTET or LKKTNT or a conservative variant thereof to improve recovery from reconstituted aqueous solutions following lyophilization.
  • the preferred amino acid stabilizers are arginine and glycine, while the most preferred 50 mM amino acid is glycine.
  • Peptide agents comprising amino acid sequences LKKTET or LKKTNT or a conservative variant thereof are administered to the surface of the eye for local effects to treat, for example:
  • Corneal epithelial wounds caused by but not limited to chemical burns, recurrent corneal erosions, epithelial debridement during surgery, corneal resurfacing procedures, Laser-assisted In Situ Keratomileusis (LASIK);
  • Ocular inflammation (alone or in combination with corticosteroids) to treat, for example, conjunctivitis, blepharitis, keratitis, uveitis, scleritis, retinitis, optic neuritis, and temporal arteritis;
  • Microbial infection (alone or in combination with antibacterial, antifungal, or antiviral agents or in combination with both antimicrobials and anti-inflammatory agents);
  • Red eye [alone or in combination with ocular decongestants (adrenergic vasoconstrictors of the conjunctiva), such as ephedrine, naphazoline, phenylephirine, tetrahydrozoline and antihistamines, such as pheniramine maleate) to whiten the eye];
  • ocular decongestants adrenergic vasoconstrictors of the conjunctiva
  • ephedrine ephedrine
  • naphazoline phenylephirine
  • antihistamines such as pheniramine maleate
  • Topical inventive peptide agents are formulated as solutions, suspensions, gels and ointments.
  • Inventive peptide agent formulations may be administered directly or indirectly by collagen sponges, inserts or the like. Every ophthalmic product, including topical ophthalmics, should be sterile in its final container to prevent microbial contamination of the eye. Preservatives are added to the formulation when packaged in a multidose container for more than one use to maintain sterility once the container has been opened.
  • Ophthalmic formulations require that the pH, buffer capacity, viscosity and tonicity of the formulation are carefully controlled. Preferred pH ranges, buffers, viscosities and tonicities have been described herein.
  • Each milliliter of a topically-applied inventive peptide formulation contains the following peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant as shown below:
  • Preferred Carrier/Vehicle 20 mM Sodium citrate; 50 mM glycine; 3% sucrose; NaOH or HCI to adjust pH; Purified water, USP.
  • particles must be less than 10 microns in size to minimize irritation to the eye. There may be a tendency of the solid undissolved particles to adhere to the conjunctiva. As drug is absorbed, these particles will dissolve to replenish the absorbed drug. This reservoir or depot effect increases the contact time and duration of action of a suspension compared to a solution.
  • Each milliliter of a topically-applied inventive peptide formulation contains the following peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant as shown below: [0073] Peptide at a concentration with a range of from about 0.001 to 1 ,000 mg/ml, preferably from about 0.01 mg/ml to 600 mg/ml, more preferably peptide at a concentration of about 0.1 mg/ml to 60 mg/ml, most preferably peptide at a concentration of about 1 mg/ml to 6 mg/ml.
  • Preferred Carrier/Vehicle Peptide-encapsulation in poly(lactide-co-glycolide) PLGA microspheres; 20 mM Sodium citrate; 50 mM glycine; 3% sucrose; NaOH or HCI to adjust pH; Purified water, USP.
  • Each milliliter of a topically-applied inventive peptide formulation contains the following peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant as shown below:
  • Preferred Carrier/Vehicle carboxymethylcellulose sodium (0.5 to 1 %); dibasic sodium phosphate; sodium chloride; propylene glycol; methylparaben; propylparaben; NaOH/HCI to adjust pH; Purified water, USP.
  • Each milliliter of a topically-applied inventive peptide formulation contains the following peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant as shown below:
  • Preferred Carrier/Vehicle (1 ) carboxymethycellulose sodium (2.5%); dibasic sodium phosphate; propylene glycol; methylparaben; propylparaben; sodium chloride; NaOH/HCI to adjust pH; purified water.
  • Preferred Carrier/Vehicle (2) "liquid” lanolin (10%); mineral oil (30%), and white petrolatum (60%).
  • Corticosteroids inhibit the inflammatory response to a variety of inciting agents.
  • Dexamethasone ophthalmic suspension 0.1%)
  • Dexamethasone ophthalmic ointment 0.05%)
  • Dexamethasone Sodium Phosphate Ophthalmic Solution 0.1%)
  • Fluorometholone Ophthalmic Ointment 0.1%)
  • Fluorometholone Ophthalmic Suspensions 0.25-1%
  • Fluorometholone Acetate Ophthalmic Suspension 0.1%)
  • the topical conjunctival route of entry plays an important role in the penetration of drugs into the anterior segment. Furthermore, topically applied drugs have been shown to have access to the sclera from the conjuctiva. The potential for transport or diffusion through the sclera lies in the large and accessible surface area of this tissue, with its high degree of hydration, hypocellularity, and permeability that do not decline significantly with age. As such, it is conceivable that inventive compositions could find their way to the posterior segment by this noninvasive route of administration.
  • inventive compositions of the peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant thereof is useful in delivering anti-inflammatory and anti-microbial regimens, sensitive to the inventive composition, to treat serious ocular inflammation and ocular infections, such as uveitis and endophthalmitis, and glaucoma.
  • Each ml of a peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant contains:
  • Preferred Carrier/Vehicle 20 mM Sodium citrate; 50 mM glycine; 3% sucrose; NaOH or HCI to adjust pH; Water for Injection, USP.
  • Topically applied drugs do penetrate into the intraocular environment through the hydrophobic cornea; however, transcorneal transport is not the most effective process as it is estimated that only one- to three-tenths of a dose penetrates into the eye while most of the drug remains confined to the superficial epithelium layer. Passive diffusion of inventive peptide compositions across the cornea is largely influenced by their solubility, molecular weight and degree of ionization. Having a net negative charge and a relatively high molecular weight, an inventive peptide agent, formulated as a topically-applied drug will find it difficult to penetrate the intact cornea.
  • inventive compositions will pass through the cornea into the intraocular space more efficiently.
  • Topical solutions, gels or ointments of peptide agents comprising amino acid sequences LKKTET or LKKTNT or conservative variants described above are suitable formulations for transcorneal instillation.
  • Periocular injection formulations of inventive peptide agents are used in cases where ocular inflammation is not responding to a topical eye drops alone and in inflammatory conditions such as anterior uveitis, posterior uveitis, endophthalmitis, and optic neuritis.
  • the peptide agent is injected just below the conjunctiva or in the space below Tenon's capsule. Here, more absorption will occur and consequently, more drug will be available to the desired site.
  • Periocular injection is additive to topical therapy but lacks the convenience and is not well-tolerated to be considered a first line treatment.
  • Each ml of the peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant contains:
  • Preferred Carrier/Vehicle 20 mM Sodium citrate; 50 mM glycine; 3% sucrose; NaOH or HCI to adjust pH; Water for Injection, USP.
  • inventive peptide agents to the intraocular tissues can be achieved by injection into the vitreous or aqueous cavitiy.
  • the vitreous is made of a hydrogel (water, hyaluronic acid and collagen), which fills the cavity between the retina and the lens, while the aqueous is a watery fluid which fills the cavity between the lens and the iris.
  • Intravitreal or intra-aqueous injections of an inventive peptide agent, formulated as a solution allows for immediate exposure of intraocular tissues to the peptide agent.
  • inventive agent which may be quickly eliminated from the vitreous, would require repeated injections that increase the risk of endophthalmitis, damage to lens, retinal detachment and may be poorly tolerated.
  • inventive peptide agent would be encapsulated within phospholipid membranes, i.e., liposomes, biodegradable microspheres, nanoparticles, or biodegradable lactone based polymers that includes polyesters made by polycondensation of L-lactide, glycolide, caprolactone, dioxanone, cyclic carbonates and their derivatives.
  • Polylactide and polyglycolide known also as poly(lactic-acid) PLA and poly(glycolic-acid) PGA, respectively, and particularly their co-polymers poly(lactide-co-glycolide) PLGA are the most investigated biodegradable polymers, which also can also be applied as carriers for the inventive peptide agents.
  • peptide-polymer conjugates such as the covalent linkage of the peptide agent comprising LKKTET or LKKTNT or a conservative variant thereof with synthetic and natural polymers such as polyethylene glycol (PEG) and dextran, including the cyclodextrans, allow for an improve pharmacokinetic profile, resulting in a decrease in inventive peptide clearance.
  • Intravitreal or intra-aqueous administration of an inventive peptide agent may be indicated in treatment of ocular inflammation, ocular infection (bacterial, fungal or viral) and the glaucomatous eye by controlling F-actin architecture in outflow pathway cells. (Read AT et al., Exp Eye Res, 2006 Jun:82(6):974-85).
  • Each ml of the peptide agent comprising amino acid sequence LKKTET or LKKTNT or a conservative variant contains:
  • Preferred Carrier/Vehicle (1 ) 20 mM Sodium citrate; 50 mM glycine; 3% sucrose; NaOH or HCI to adjust pH; Water for Injection, USP.
  • Preferred Carrier/Vehicle (2) Peptide encapsulation in PLGA microspheres; 20 mM Sodium citrate; 50 mM glycine; 3% sucrose; NaOH or HCI to adjust pH; Water for Injection, USP.
  • a composition according to another embodiment is for administration to skin tissue of a subject, and comprises a peptide agent comprising amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in said tissue, the composition further comprising a quaternary ammonium salt and a topical carrier for application to skin tissue of said subject.
  • the peptide agent may comprise amino acid sequence LKKTET, amino acid sequence LKKTETQ, T ⁇ 4, an N-terminal variant of T ⁇ 4, or an isoform of T ⁇ 4.
  • the quaternary ammonium salt may comprise benzalkonium chloride.
  • the peptide agent may be at a concentration of about 0.001 - 1 ,000 mg/ml and said quaternary ammonium salt may be present in said composition at about 0.001 - 1 % by weight.
  • the composition may be in a form of a solution, gel, cream, paste, lotion, spray, suspension, dispersion, salve, hydrogel, ointment or foam formulation.
  • the composition may be a cosmetic formulation.
  • compositions of thymosin beta 4 were formulated in a stabilizing solution (SS).
  • the compositions are shown in Tables 1 , 2 and 3 below.
  • Table 1 Composition of Thymosin ⁇ 4 Opthalmic Drug Product, 0.01%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de stabilisation d'un polypeptide à l'extérieur d'un corps combinant le polypeptide à une solution aqueuse qui inclut des niveaux pratiquement physiologiques d'électrolytes et de sels.
PCT/US2008/002261 2007-03-06 2008-02-21 Procédés et compositions de stabilisation de polypeptides WO2008108927A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90505107P 2007-03-06 2007-03-06
US60/905,051 2007-03-06

Publications (2)

Publication Number Publication Date
WO2008108927A2 true WO2008108927A2 (fr) 2008-09-12
WO2008108927A3 WO2008108927A3 (fr) 2008-12-04

Family

ID=39738962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002261 WO2008108927A2 (fr) 2007-03-06 2008-02-21 Procédés et compositions de stabilisation de polypeptides

Country Status (1)

Country Link
WO (1) WO2008108927A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20160143610A (ko) * 2016-11-29 2016-12-14 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
JP2017533262A (ja) * 2014-10-22 2017-11-09 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
US20180228729A1 (en) * 2015-10-06 2018-08-16 G-Treebnt Co., Ltd. Method for preparing ophthalmic preparation containing thymosin beta-4
JP2018523648A (ja) * 2015-08-18 2018-08-23 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンベータ４およびクエン酸を活性成分として含む角膜損傷予防／治療用組成物
CN110430866A (zh) * 2017-03-03 2019-11-08 Gtreebnt科技有限公司 含有胸腺素β-4作为有效成分的稳定外用剂
US20220096404A1 (en) * 2019-01-14 2022-03-31 Medivis S.R.L. Chemically and physically stable topical ophthalmic nepafenac-based formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHI E.Y. ET AL.: 'Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation' PHARM. RES. vol. 20, no. 9, September 2003, pages 1325 - 1336, XP002475010 *
GOLDSTEIN A.L. ET AL.: 'Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues' TRENDS IN MOLECULAR MEDICINE vol. 11, no. 9, September 2005, pages 421 - 429, XP005065335 *
PHILP D. ET AL.: 'Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice in aged mice' WOUND REPAIR AND REGENERATION vol. 11, no. 1, January 2003 - February 2003, pages 19 - 24, XP002441696 *
WANG W. ET AL.: 'Antibody Structure, Instability, and Formulation' J. PHARM. SCI. vol. 96, no. 1, January 2007, pages 1 - 26, XP009084505 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085619B2 (en) 2007-11-30 2015-07-21 Abbvie Biotechnology Ltd. Anti-TNF antibody formulations
US11191834B2 (en) 2007-11-30 2021-12-07 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US11167030B2 (en) 2007-11-30 2021-11-09 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US10406208B2 (en) 2014-10-22 2019-09-10 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
JP2017533262A (ja) * 2014-10-22 2017-11-09 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
EP3210614A4 (fr) * 2014-10-22 2018-06-13 G-Treebnt Co., Ltd. Composition contenant de la thymosine bêta 4 et formulation pharmaceutique la contenant
AU2015336396B2 (en) * 2014-10-22 2020-12-10 HLB Therapeutics Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
JP2018523648A (ja) * 2015-08-18 2018-08-23 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンベータ４およびクエン酸を活性成分として含む角膜損傷予防／治療用組成物
EP3338792A4 (fr) * 2015-08-18 2019-05-15 G-Treebnt Co., Ltd. Composition de prévention/traitement de lésions de la cornée comportant comme principes actifs de la thymosine bêta 4 et de l'acide citrique
US20180228729A1 (en) * 2015-10-06 2018-08-16 G-Treebnt Co., Ltd. Method for preparing ophthalmic preparation containing thymosin beta-4
JP2018531905A (ja) * 2015-10-06 2018-11-01 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンベータ４を含む眼科用製剤の製造方法
JP6996713B2 (ja) 2015-10-06 2022-02-04 エイチエルビー・セラピューティクス・カンパニー・リミテッド チモシンベータ４を含む眼科用製剤の製造方法
EP3342398A4 (fr) * 2015-10-06 2019-03-20 G-Treebnt Co., Ltd. Procédé de préparation de préparation ophtalmique contenant de la thymosine bêta-4
US10744088B2 (en) 2015-10-06 2020-08-18 G-Treebnt Co., Ltd. Method for preparing ophthalmic preparation containing thymosin beta-4
JP2020183391A (ja) * 2015-10-06 2020-11-12 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンベータ４を含む眼科用製剤の製造方法
KR20160143610A (ko) * 2016-11-29 2016-12-14 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
KR102115158B1 (ko) * 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
EP3590497A4 (fr) * 2017-03-03 2020-12-30 G-Treebnt Co., Ltd. Agent stabilisé à usage externe comprenant de la thymosine bêta-4 comme ingrédient actif
US11179443B2 (en) 2017-03-03 2021-11-23 G-Treebnt Co., Ltd. Stabilized external preparation comprising thymosin beta 4 as an active ingredient
CN110430866A (zh) * 2017-03-03 2019-11-08 Gtreebnt科技有限公司 含有胸腺素β-4作为有效成分的稳定外用剂
JP2020508970A (ja) * 2017-03-03 2020-03-26 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンベータ−４を有効成分として含有する安定化外用剤
CN110430866B (zh) * 2017-03-03 2023-04-07 Hlb医疗有限公司 含有胸腺素β-4作为有效成分的稳定外用剂
US20220096404A1 (en) * 2019-01-14 2022-03-31 Medivis S.R.L. Chemically and physically stable topical ophthalmic nepafenac-based formulations

Also Published As

Publication number Publication date
WO2008108927A3 (fr) 2008-12-04

Similar Documents

Publication Publication Date Title
US10004785B2 (en) LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
JP5736635B2 (ja) ドライアイ治療剤
JP5549669B2 (ja) 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
JP5673531B2 (ja) 眼科用組成物
WO2008108927A2 (fr) Procédés et compositions de stabilisation de polypeptides
CN101198344A (zh) 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
EP4029493A1 (fr) Composition ophtalmique en nanoémulsion comprenant de la cyclosporine et du menthol, et son procédé de préparation
JPWO2018074421A1 (ja) 眼科用剤及び眼科用薬
EP3229780B1 (fr) Compositions ophtalmiques destinées à être utilisées dans le traitement du syndrome de l'oeil sec

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725854

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08725854

Country of ref document: EP

Kind code of ref document: A2